NASDAQ · ZURA
Healthcare · Biotechnology
$4.04
Up+$0.19 (+4.94%)
Updated Nov 1, 2026, 6:38 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ZURA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
ZURA closed at $4.04 after 20 trading sessions, up 2.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $3.81 | $4.06 | $3.655 | $4.04 | 4.08M |
| Oct 29, 2026 | $4.35 | $4.49 | $3.80 | $3.85 | 3.35M |
| Oct 28, 2026 | $4.23 | $4.60 | $4.11 | $4.35 | 4.39M |
| Oct 27, 2026 | $3.57 | $4.33 | $3.4117 | $4.27 | 5.09M |
| Oct 26, 2026 | $3.35 | $3.80 | $3.345 | $3.56 | 4.29M |
| Oct 23, 2026 | $3.54 | $3.595 | $3.27 | $3.36 | 5.82M |
| Oct 22, 2026 | $4.38 | $4.47 | $3.50 | $3.53 | 8.81M |
| Oct 21, 2026 | $4.05 | $4.235 | $3.96 | $4.13 | 4.19M |
| Oct 20, 2026 | $3.83 | $4.21 | $3.81 | $4.00 | 3.32M |
| Oct 19, 2026 | $3.91 | $4.06 | $3.77 | $3.81 | 4.56M |
| Oct 16, 2026 | $4.30 | $4.35 | $3.86 | $3.88 | 4.91M |
| Oct 15, 2026 | $4.42 | $4.50 | $4.15 | $4.28 | 5M |
| Oct 14, 2026 | $4.23 | $4.615 | $4.17 | $4.41 | 5.76M |
| Oct 13, 2026 | $3.95 | $4.78 | $3.85 | $4.23 | 24.44M |
| Oct 12, 2026 | $4.00 | $4.12 | $3.9451 | $4.00 | 1.61M |
| Oct 9, 2026 | $4.13 | $4.35 | $4.00 | $4.00 | 1.71M |
| Oct 8, 2026 | $4.12 | $4.16 | $3.905 | $4.13 | 2.7M |
| Oct 7, 2026 | $3.96 | $4.35 | $3.90 | $4.17 | 2.08M |
| Oct 6, 2026 | $3.97 | $4.055 | $3.82 | $3.96 | 1.43M |
| Oct 5, 2026 | $4.11 | $4.19 | $3.92 | $3.93 | 2.65M |
The latest Smart Investors Daily articles mentioning ZURA.
Company
Market Activity
Research & News
ZURA research
Company profile and research snapshot.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Wedbush | Outperform | — |
| Aug 12, 2026 | Guggenheim | Buy | — |
| Jul 8, 2026 | William Blair | Outperform | — |
| Jul 1, 2026 | Wedbush | Outperform | — |
| Mar 23, 2026 | Chardan Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and
Benzinga · Feb 27, 2026
Yahoo · Feb 25, 2026
This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.
Yahoo · Feb 25, 2026
RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ZURA.
